TNFα and Immune Checkpoint Inhibition: Friend or Foe for Lung Cancer?

Benoot, Thomas; Piccioni, Elisa; Ridder, Kirsten De; Goyvaerts, Cleo

doi:10.3390/ijms22168691

Cited by 31 publications

(22 citation statements)

References 134 publications

(161 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Article https://doi.org/10.1038/s41467-022-33052-y on angiogenesis 70 , as its promoting/inhitibory effect on angiogenesis is context-dependent 71 . Despite cDCs not being enriched in the tumor setting in our dataset (Supplementary Data 4, 5), these results nevertheless highlight the putative importance of further investigation into cDC-EC crosstalk in light of tumor angiogenesis in BC.…”

Section: Endothelial-immune Cell Interactome Predictionsmentioning

confidence: 99%

Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast

et al. 2022

View full text Add to dashboard Cite

Since a detailed inventory of endothelial cell (EC) heterogeneity in breast cancer (BC) is lacking, here we perform single cell RNA-sequencing of 26,515 cells (including 8433 ECs) from 9 BC patients and compare them to published EC taxonomies from lung tumors. Angiogenic ECs are phenotypically similar, while other EC subtypes are different. Predictive interactome analysis reveals known but also previously unreported receptor-ligand interactions between ECs and immune cells, suggesting an involvement of breast EC subtypes in immune responses. We also identify a capillary EC subtype (LIPEC (Lipid Processing EC)), which expresses genes involved in lipid processing that are regulated by PPAR-γ and is more abundant in peri-tumoral breast tissue. Retrospective analysis of 4648 BC patients reveals that treatment with metformin (an indirect PPAR-γ signaling activator) provides long-lasting clinical benefit and is positively associated with LIPEC abundance. Our findings warrant further exploration of this LIPEC/PPAR-γ link for BC treatment.

show abstract

Section: Endothelial-immune Cell Interactome Predictionsmentioning

confidence: 99%

Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Benoot et al. evaluated the numerous contradictory findings of TNFα application in lung cancer ( 138 ), bringing to our awareness the varied functions of various TNF family members and the positive impacts of TNF signaling. Modern genomic, transcriptomic, and proteomic techniques are useful for identifying signaling events and molecules in signal transduction ( 139 , 140 ).…”

Section: Mechanisms Related To Inflammation In Rpmentioning

confidence: 99%

Neuroinflammation in retinitis pigmentosa: Therapies targeting the innate immune system

Ling

Hou²,

Yan³

2022

Front. Immunol.

View full text Add to dashboard Cite

Retinitis pigmentosa (RP) is an important cause of irreversible blindness worldwide and lacks effective treatment strategies. Although mutations are the primary cause of RP, research over the past decades has shown that neuroinflammation is an important cause of RP progression. Due to the abnormal activation of immunity, continuous sterile inflammation results in neuron loss and structural destruction. Therapies targeting inflammation have shown their potential to attenuate photoreceptor degeneration in preclinical models. Regardless of variations in genetic background, inflammatory modulation is emerging as an important role in the treatment of RP. We summarize the evidence for the role of inflammation in RP and mention therapeutic strategies where available, focusing on the modulation of innate immune signals, including TNFα signaling, TLR signaling, NLRP3 inflammasome activation, chemokine signaling and JAK/STAT signaling. In addition, we describe epigenetic regulation, the gut microbiome and herbal agents as prospective treatment strategies for RP in recent advances.

show abstract

“…TNFRSF members can stimulate T-cell responsiveness and define niches for T cell memory ( 21 , 22 ). Several TNFRSF members have been identified as emerging cancer immunotherapy targets ( 23 – 25 ). Unfortunately, the expression profile and clinical relevance of the TNF family in SCLC remain poorly understood.…”

Section: Introductionmentioning

confidence: 99%

Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer

Zhang

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Tumor necrosis factor (TNF) family members participate in the body’s antitumor immunity response and influence tumor prognosis and treatment response. However, little is known about the roles of TNF family members in small cell lung cancer (SCLC). Therefore, we conducted the first comprehensive investigation of TNF family members in patients with SCLC, with the goal of using them to predict prognosis and chemotherapy benefit. Abnormal genetic alterations and expression of TNF family members were found to be widespread in SCLC patients. Using LASSO Cox regression analysis, we constructed a TNF family-based signature that separated SCLC patients in the training set (n=77) into high- and low-risk groups with distinct survival and chemotherapy benefit, and the signature was well-validated in the validation set (n=137) by RT-qPCR. Importantly, the signature exhibited superior predictive performance and was identified as a novel independent prognostic factor. Additionally, different immune phenotypes were found between the low-risk and high-risk groups, and high-risk patients had higher CMTM6 expression, suggesting that these patients could benefit from therapeutic methods targeting CMTM6. We constructed the first clinically applicable TNF family-based signature for predicting prognosis and chemotherapy benefit for patients with SCLC. The findings reported here provide a new method for predicting the prognosis of SCLC patients and optimizing clinical management.

show abstract

TNFα and Immune Checkpoint Inhibition: Friend or Foe for Lung Cancer?

Cited by 31 publications

References 134 publications

Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast

Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast

Neuroinflammation in retinitis pigmentosa: Therapies targeting the innate immune system

Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer

Contact Info

Product

Resources

About